Malaria-induced bacteremia has been shown to result from intestinal mast cell (MC) activation. The appearance of MCs in the ileum and increased intestinal permeability to enteric bacteria are preceded by an early Th2-biased host immune response to infection, characterized by the appearance of IL-4, IL-10, mast cell protease (Mcpt)1 and Mcpt4, and increased circulating basophils and eosinophils. Given the functional similarities of basophils and MCs in the context of allergic inflammation and the capacity of basophils to produce large amounts of IL-4, we sought to define the role of basophils in increased intestinal permeability, in MC influx, and in the development of bacteremia in the context of malaria. Upon infection with nonlethal Plasmodium yoelii yoelii 17XNL, Basoph8 × ROSA-DTα mice or baso (−) mice that lack basophils exhibited increased intestinal permeability and increased ileal MC numbers, without any increase in bacterial 16S ribosomal DNA copy numbers in the blood, relative to baso (+) mice. Analysis of cytokines, chemokines, and MC-associated factors in the ileum revealed significantly increased TNF-α and IL-13 at day 6 postinfection in baso (−) mice compared with baso (+) mice. Moreover, network analysis of significantly correlated host immune factors revealed profound differences between baso (−) and baso (+) mice following infection in both systemic and ileal responses to parasites and translocated bacteria. Finally, basophil depletion was associated with significantly increased gametocytemia and parasite transmission to Anopheles mosquitoes, suggesting that basophils play a previously undescribed role in controlling gametocytemia and, in turn, mammalian host-to-mosquito parasite transmission.
Our previous work demonstrated that basophils regulate a suite of malaria phenotypes, including intestinal mastocytosis and permeability, the immune response to infection, gametocytemia, and parasite transmission to the malaria mosquito Anopheles stephensi. Given that activated basophils are primary sources of the regulatory cytokines IL-4 and IL-13, we sought to examine the contributions of these mediators to basophil-dependent phenotypes in malaria. We generated mice with basophils depleted for IL-4 and IL-13 (baso IL-4/IL-13 (−)) and genotype controls (baso IL-4/IL-13 (+)) by crossing mcpt8-Cre and Il4/Il13fl/fl mice and infected them with Plasmodium yoelii yoelii 17XNL. Conditional deletion was associated with ileal mastocytosis and mast cell (MC) activation, increased intestinal permeability, and increased bacterial 16S levels in blood, but it had no effect on neutrophil activation, parasitemia, or transmission to A. stephensi. Increased intestinal permeability in baso IL-4/IL-13 (−) mice was correlated with elevated plasma eotaxin (CCL11), a potent eosinophil chemoattractant, and increased ileal MCs, proinflammatory IL-17A, and the chemokines MIP-1α (CCL3) and MIP-1β (CCL4). Blood bacterial 16S copies were positively but weakly correlated with plasma proinflammatory cytokines IFN-γ and IL-12p40, suggesting that baso IL-4/IL-13 (−) mice failed to control bacterial translocation into the blood during malaria infection. These observations suggest that basophil-derived IL-4 and IL-13 do not contribute to basophil-dependent regulation of parasite transmission, but these cytokines do orchestrate protection of intestinal barrier integrity after P. yoelii infection. Specifically, basophil-dependent IL-4/IL-13 control MC activation and prevent infection-induced intestinal barrier damage and bacteremia, perhaps via regulation of eosinophils, macrophages, and Th17-mediated inflammation.
We have recently demonstrated that basophils are protective against intestinal permeability during malaria and contribute to reduced parasite transmission to mosquitoes. Given that IL-18 is an early cytokine/alarmin in malaria and has been shown to activate basophils, we sought to determine the role of the basophil IL-18R in this protective phenotype. To address this, we infected control [IL18rflox/flox or basoIL-18R (+)] mice and mice with basophils lacking the IL-18R [IL18rflox/flox × Basoph8 or basoIL-18R (−)] with Plasmodium yoelii yoelii 17XNL, a nonlethal strain of mouse malaria. Postinfection (PI), intestinal permeability, ileal mastocytosis, bacteremia, and levels of ileal and plasma cytokines and chemokines were measured through 10 d PI. BasoIL-18R (−) mice exhibited greater intestinal permeability relative to basoIL-18R (+) mice, along with increased plasma levels of proinflammatory cytokines at a single time point PI, day 4 PI, a pattern not observed in basoIL-18R (+) mice. Surprisingly, mosquitoes fed on basoIL-18R (−) mice became infected less frequently than mosquitoes fed on basoIL-18R (+) mice, with no difference in gametocytemia, a pattern that was distinct from that observed previously with basophil-depleted mice. These findings suggest that early basophil-dependent protection of the intestinal barrier in malaria is mediated by IL-18, and that basophil IL-18R–dependent signaling differentially regulates the inflammatory response to infection and parasite transmission.
Background/Objectives: Maternal Autoantibody-Related Autism (MARA) is a recently defined subset of autism characterized by specific combinations of maternal autoantibodies which cross the placenta and bind neurodevelopmentally critical target proteins. A clinical multi-ELISA MARA assay was recently rigorously analytically validated. The primary objective of this study was to assess the potential performance of this MARA autoantibody assay for predicting autism risk in high-risk populations. Secondary objectives were to establish the significant MARA autoantibody combinations and verify clinical discrimination in an external cohort. Methods: Bio-banked plasma samples from mothers of 420 autism and 335 typically developing (TD) children were analyzed by ELISA for MARA autoantibodies in combination. “Transcendent” autoantibody pairwise combinations were identified in discovery where both autoantibodies in a combination exceeded the values of every control participant. Permutation testing was used to establish that the probability of observed results significantly exceeded chance. Performance was then validated in an independent cohort (mothers of 42 autistic and 90 TD children). Results: “Transcendent” antibody levels were discovered in 70 mothers (16.7% of autism cases; no typically developing participants) in the discovery cohort. Specificity and positive predictive values for autism were 100% by construct. An external cohort showed similar performance with 14 (33.3%) transcendents. Permutation testing of each cohort demonstrated probabilities of transcendent cases to be significantly higher than expected be chance. Conclusions: The data reported here provides evidence for a high-risk subset of mothers of children with autism identified by the MARA autoantibody assay which enables further clinical validation.
Background/Objectives: Specific combinations of maternal autoantibodies targeting fetal brain proteins are associated with Maternal Autoantibody-Related Autism (MARA), a biologically defined subset of autism. We previously translated a multi-ELISA assay to detect MARA-associated autoantibodies and identify mothers with transcendent levels of specific autoantibody combinations that exceed that of controls and are highly predictive of autism in their offspring. Our objective here was to derive a rule-based classifier, a “test table” of autoantibody pairwise combinations, each with pair-specific thresholds, and to validate its clinical performance characteristics by cross-validation. Methods: Plasma samples from mothers of 482 autism and 425 typically developing children were analyzed in a clinical lab for previously identified predictive combinations of autoantibodies. Stratified 20-fold cross-validation in all 907 participants assessed test table stability and predictive performance. The most stable test table was retrained on the full cohort to establish optimal thresholds and determine performance. Permutation testing assessed performance relative to chance. Results: Cross-validated performance showed a mean specificity across folds of 99.8%, an imputed mean PPV of 97.5%, a detection rate of 4.4%, and a positive likelihood ratio (LR+) of 18.5. Applied in-sample to the full cohort, the final test table detected 6.2% of cases with no false positives, giving an upper-range LR+ estimate of 26.5. Conclusion: The high specificity, PPV, and positive likelihood ratio of this assay support its potential clinical implementation for identifying a subset of mothers at very high risk of having a child with autism, and as a companion diagnostic for interventions targeting the MARA subtype of autism.